FANJ
ACAD icon

Financial Architects (New Jersey)’s Acadia Pharmaceuticals ACAD Stock Holding History

Financial Architects (New Jersey)’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-774
Closed -$38K – 276
2020
Q2 		$38K Buy
+774
New +$37.2K 0.01% 461
2019
Q2 		– Sell
-670
Closed -$18K – 1181
2019
Q1 		$18K Sell
670
-200
-23% -$4.67K ﹤0.01% 912
2018
Q4 		$14K Buy
870
+200
+30% +$3.88K ﹤0.01% 902
2018
Q3 		$14K Sell
670
-450
-40% -$7.08K ﹤0.01% 1006
2018
Q2 		$17K Buy
1,120
+200
+22% +$3.57K ﹤0.01% 844
2018
Q1 		$21K Buy
920
+350
+61% +$9.69K ﹤0.01% 869
2017
Q4 		$17K Buy
570
+450
+375% +$14.4K ﹤0.01% 1005
2017
Q3 		$5K Sell
120
-1,100
-90% -$35.8K ﹤0.01% 1261
2017
Q2 		$34K Buy
1,220
+800
+190% +$23.8K 0.01% 799
2017
Q1 		$14K Sell
420
-630
-60% -$22.2K ﹤0.01% 1039
2016
Q4 		$30K Sell
1,050
-350
-25% -$9.26K 0.01% 715
2016
Q3 		$45K Buy
1,400
+800
+133% +$27.1K 0.01% 597
2016
Q2 		$19K Buy
+600
New +$20.1K 0.01% 793

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return

Financial Architects (New Jersey)'s ACAD Position: Q3 2020 in Review

Financial Architects (New Jersey) sold out of Acadia Pharmaceuticals (ACAD) in Q3 2020, closing a stake of 774 shares — an estimated $38K sold.

Financial Architects (New Jersey) first reported a position in ACAD in Q2 2016 and held it in 13 quarters. The position peaked at $45K in Q3 2016. 267 funds tracked by Wall St. Rank hold ACAD as of Q3 2020.

  • Financial Architects (New Jersey) reported no remaining Acadia Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
  • Financial Architects (New Jersey) sold 774 Acadia Pharmaceuticals shares in Q3 2020, an estimated $38K.
  • Financial Architects (New Jersey) first reported a position in Acadia Pharmaceuticals in Q2 2016 and held it in 13 quarters.
  • Financial Architects (New Jersey)'s Acadia Pharmaceuticals position peaked at $45K in Q3 2016.
  • 267 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q3 2020.

Based on Financial Architects (New Jersey)'s 13F filing for Q3 2020, filed 9 Nov 2020.